Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Holding AU:CHM?
Track your performance easily
CHM Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week Range<AU$0.01 - AU$0.04
Previous CloseAU$0.01
Volume774.86K
Average Volume (3M)3.24M
Market Cap
AU$9.45M
Enterprise Value-AU$8.93M
Total Cash (Recent Filing)AU$18.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Feb 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume6,077,412
30 Day Avg. Volume3,241,359
Standard Deviation0.20
R-Squared0.19
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)21654.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Chimeric Therapeutics Ltd. News
PremiumCompany Announcements
Chimeric Therapeutics Advances Innovative AML Trial
PremiumCompany Announcements
Chimeric Therapeutics Expands Director’s Securities Portfolio
PremiumCompany Announcements
Chimeric Therapeutics Issues New Equity Options
PremiumCompany Announcements
Chimeric Therapeutics Sees Increased Stake by Paul Hopper
PremiumCompany Announcements
Chimeric Therapeutics Updates on Unquoted Securities
PremiumCompany Announcements
Chimeric Therapeutics Issues New Equity Securities
PremiumCompany Announcements
Chimeric Therapeutics Expands Market Presence with ASX Quotation
PremiumCompany Announcements
Chimeric Therapeutics Gains Shareholder Approval for GrowthOptions Prices
Currently, No data available
---
Ownership Overview
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Currently, no data Available
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Feb 19, 2025 which is in 58 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Aug 30, 2024. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.017.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 1,575,149,900 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
---
Chimeric Therapeutics Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CHM Sentiment 82%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$800.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-308.21%
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells.
---
Australian Clinical Labs Ltd
―
Race Oncology Ltd.
―
Radiopharm Theranostics Limited
―
---